Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
McKesson
Moodys
Express Scripts
Mallinckrodt

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR COLCRYS

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Colcrys

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01001052 Relative Bioavailability of Colcrys™ 0.6 mg Tablets in Healthy Young and Elderly Volunteers Under Fasted Conditions Completed Mutual Pharmaceutical Company, Inc. Phase 1 2009-10-01 The purpose of this study is to evaluate and compare the relative bioavailability of a single dose of Colcrys™ (colchicine) 0.6 mg when administered to a group of young , healthy subjects 18-30 years of age compared to a group of older, generally healthy subjects 60 years of age or older following an overnight fast.
NCT01084278 Healthy and Renal Impairment Study of Colcrys (Colchicine, USP) Completed Takeda Phase 4 2010-05-01 The primary objective of this study is to compare the pharmacokinetic profiles of colchicine and its primary metabolites in plasma and urine following a single 0.6 mg oral dose of colchicine in healthy adults with normal renal function, in patients with mild, moderate or severe renal impairment, and in patients with end-stage renal disease on hemodialysis. An additional objective of this study is to study the clearance of colchicine and its metabolites by hemodialysis. Secondary objectives include evaluation of the safety and tolerability of colchicine in the study population.
NCT01112982 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed Takeda Pharmaceuticals North America, Inc. Phase 4 2010-05-01 The purpose of this study is to show that patients with gout suffer from chronic inflammation of their joints, observable by MRI, even in the absence of symptomatic gouty attacks. Secondary end-points of this study will include analyzing the effects of uric acid-lowering therapy (specifically with the FDA approved medication Febuxostat) in a subgroup of patients, checking for the presence of inflammatory markers to see if there is any correlation with the proposed chronic inflammation, and evaluating for other characteristic findings of gout on MRI.
NCT01112982 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels. Completed University of South Florida Phase 4 2010-05-01 The purpose of this study is to show that patients with gout suffer from chronic inflammation of their joints, observable by MRI, even in the absence of symptomatic gouty attacks. Secondary end-points of this study will include analyzing the effects of uric acid-lowering therapy (specifically with the FDA approved medication Febuxostat) in a subgroup of patients, checking for the presence of inflammatory markers to see if there is any correlation with the proposed chronic inflammation, and evaluating for other characteristic findings of gout on MRI.
NCT01123395 Bioavailability Study of Colcrys® in Apple Juice Completed Mutual Pharmaceutical Company, Inc. Phase 1 2010-05-01 The purpose of this study is to evaluate and compare the relative bioavailability of a single 0.6 mg tablet of Colcrys® (colchicine, USP) when crushed and dissolved in apple juice relative to the same dose given as an intact tablet to healthy subjects following an overnight fast.
NCT01130051 Bioavailability Study of Colcrys® Crushed and Sprinkled on Applesauce Completed Mutual Pharmaceutical Company, Inc. Phase 1 2010-05-01 The purpose of this study is to evaluate and compare the relative bioavailability of a single 0.6 mg tablet of Colcrys® (colchicine, USP) when crushed and sprinkled on applesauce (1 tablespoon) relative to the same dose given as an intact tablet to healthy subjects following an overnight fast. A secondary objective is to evaluate the safety and tolerability of this regimen in healthy volunteers. All study subjects will be monitored for adverse events throughout the study period.
NCT01416402 Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients Completed CymaBay Therapeutics, Inc. Phase 2 2011-08-01 The purpose of this study is to determine whether arhalofenate is safe and effective when dosed in combination with febuxostat in lowering serum uric acid in patients with gout.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Colcrys

Condition Name

Condition Name for Colcrys
Intervention Trials
Healthy 4
Gout 3
Coronary Artery Disease 3
Manipulation Under Anesthesia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Colcrys
Intervention Trials
Coronary Artery Disease 3
Myocardial Ischemia 3
Coronary Disease 3
Gout 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Colcrys

Trials by Country

Trials by Country for Colcrys
Location Trials
United States 12
China 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Colcrys
Location Trials
New York 3
Maryland 2
Nevada 2
Florida 2
California 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Colcrys

Clinical Trial Phase

Clinical Trial Phase for Colcrys
Clinical Trial Phase Trials
Phase 4 6
Phase 2 6
Phase 1 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Colcrys
Clinical Trial Phase Trials
Completed 9
Recruiting 5
Withdrawn 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Colcrys

Sponsor Name

Sponsor Name for Colcrys
Sponsor Trials
Mutual Pharmaceutical Company, Inc. 3
Johns Hopkins University 2
National Heart, Lung, and Blood Institute (NHLBI) 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Colcrys
Sponsor Trials
Other 11
Industry 7
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Baxter
Merck
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.